19.01.2016 • NewsDede WillamsLawsuitlitigation

US Merck Resolves Latest Vioxx Lawsuit

In an out-of-court settlement with plaintiffs in a multi-district class action lawsuit brought by shareholders in a New Jersey federal court, US drugmaker Merck & Co has agreed to pay $830 million to resolve the claims, plus an additional amount for approved attorneys’ fees and expenses. Merck said a small portion of the payout is covered by insurance. It will take an undisclosed charge for the fourth quarter of 2015, which will be excluded from non-GAAP results.

The company said the settlement class is made up of persons who purchased its securities between May 21, 1999 and Oct. 29, 2004 and who have sought to recover damages under the federal securities laws for “certain Merck statement” regarding the painkiller Vioxx.

In the suit, the shareholders claimed Merck made “false and misleading statements” about the drug’s safety. They alleged also that they paid inflated prices the shares because of the company’s conduct.

Merck withdrew the drug 11 years ago after a colon-polyp prevention study showed it more than doubled the risk of heart attacks or stroke after 18 months of use. According to reports, as many as 38,000 people died from Vioxx-related side effects, and about 160,000 patients suffered internal injuries and damage.

With the latest settlement, the company’s total payouts to settle Vioxx-safety-related litigation has risen to at least $6 billion, said the newspaper Wall Street Journal, adding that this is in addition to its own legal-defense costs. Some related litigation is still pending.

Merck said the agreement, which is subject to court approval, does not constitute any admission of any liability or wrongdoing.

Company

Logo:

Merck & Co

126 East Lincoln Avenue
07065 Rahway
US

Company contact







Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.